India Extends Grants To Drug Makers For Neglected Diseases
This article was originally published in PharmAsia News
Executive Summary
A Cabinet committee of the Indian government approved a provision to extend grants to drug makers to encourage development of drugs for neglected diseases. The grants would include research for treatments for malaria, tuberculosis, kala-azar, filariasis and other diseases pharma companies are generally not developing, but which are considered a threat in tropical India. Under the current plan that would be extended by the Cabinet Committee on Economic Affairs, drug makers would be eligible for soft loans for up to 70 percent of the total project cost at 3 percent interest for 10 years. (Click here for more
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.